EURETINA

Additional previous surgeries and the duration of the SO tamponade had little or no impact

Yousif Subhi, MD, PhD, delivered the Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC."

We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA

Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.

Researchers in Portugal investigated Usher syndrome, Senior-Loker syndrome and other ciliopathies

Why having a set process for diagnostic imaging is crucial to patient outcomes

Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

A case series illuminates neuro-ophthalmologic manifestations, retinal vascular involvement and other pathologies

The research team used spectral-domain OCT and OCT angiography imaging to study the changes in the retinal microvasculature in patients

Dr Margaret A. Chang shares data on the port delivery system with ranibizumab, and her strategy for making the most of conferences

Businesses in the retina care space tease new technologies and cutting-edge therapeutics

Focus on collaboration, career development, and innovation

As part of the Barcelona meeting, retina specialists can recognise the awareness day early

The award, supported by Oculis, will recognize outstanding contributions to retina research and will grant €30,000 for research support, and an additional €5,000 directly to the candidate.

In the data shared, switching to SB15 from AFL maintained comparable clinical efficacy and safety in treating patients with neovascular age-related macular degeneration (nAMD), confirming biosimilarity between these agents before and after switching.

Phase 2/3 SIGLEC trial are underway. Data shared at EURETINA 2023 shows continued safety with no drug-related adverse events thus far in cohorts 1, 2, 3, and 4.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

The 23rd annual EURETINA Congress took place in Amsterdam, the Netherlands. We spoke with Arshad M. Khanani, MD, MA, FASRS, who provided an overview of his presentation, "Emerging therapies for exudative AMD."

Few injections lowers treatment burden and maintains safety profile.

The new range of pure and premixed gases are intended for medium-term use in retinal surgery.

Ali Erginay, MD, of Lariboisière Hospital in Paris, France, discusses his EURETINA presentation, "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging."

We spoke with Michael Singer, MD who provided an overview of his presentation and his work with Nanoscope Therapeutics, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial."

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.

Case 1 highlights the potential for this treatment for patients with dry AMD with noted letter gains

Robyn Guymer, MBBS, PhD, Deputy Director, Centre for Eye Research Australia, and Professor of Surgery (Ophthalmology), University of Melbourne, Australia, discussed the study findings at the 23rd annual Euretina Congress, Amsterdam.

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery."

Attendees can take advantage of many satellite symposia sponsored by industry. Experts from around the world will present during the symposia.

Experts in all aspects of retinal care will gather at the RAI Amsterdam Convention Centre, located in the Zuidas business district of the city, which is a short distance from historic Amsterdam with is canals, museums, and shops.

Automated quantitative fluid analyses are enabling personalised treatments, better patient outcomes

According to a presentation by Oculis at EURETINA, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.